Trial Profile
Phase III trial of arterolane/piperaquine in paediatric patients with uncomplicated Plasmodium falciparum malaria
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 21 Jan 2015
Price :
$35
*
At a glance
- Drugs Arterolane/piperaquine (Primary)
- Indications Falciparum malaria
- Focus Registrational; Therapeutic Use
- Sponsors Ranbaxy Laboratories
- 21 Jan 2015 New trial record
- 15 Dec 2014 ThIs phase III trial of a paediatric formulation is being conducted, according to a Ranbaxy Laboratories media release.